Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-19
2011-07-19
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255010
Reexamination Certificate
active
07981895
ABSTRACT:
This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula:The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
REFERENCES:
patent: 5834249 (1998-11-01), Furukawa et al.
patent: 6380258 (2002-04-01), Bedell
patent: 6492394 (2002-12-01), Billledeau et al.
patent: 6683078 (2004-01-01), Barta et al.
patent: 6696449 (2004-02-01), Bedell
patent: 7115632 (2006-10-01), Bedell
patent: 2005/0143385 (2005-06-01), Watkins et al.
patent: 0574758 (1993-12-01), None
patent: 0684240 (1995-11-01), None
patent: 0827742 (1998-03-01), None
patent: 10-114681 (1998-05-01), None
patent: WO 99/02510 (1999-01-01), None
patent: WO 99/24399 (1999-05-01), None
patent: WO 00/12477 (2000-03-01), None
patent: WO 00/12478 (2000-03-01), None
patent: WO/00/37436 (2000-06-01), None
patent: WO 00/37436 (2000-06-01), None
patent: WO 00/46221 (2000-08-01), None
patent: WO 00/56704 (2000-09-01), None
patent: WO 00/69819 (2000-11-01), None
patent: WO 00/69839 (2000-11-01), None
patent: WO 01/10834 (2001-02-01), None
patent: WO 01/38322 (2001-05-01), None
patent: WO 01/44189 (2001-06-01), None
patent: WO 01/62751 (2001-08-01), None
patent: WO 01/85680 (2001-11-01), None
patent: WO 01/87870 (2001-11-01), None
patent: WO 02/22577 (2002-03-01), None
patent: WO 02/26696 (2002-04-01), None
patent: WO 02/26703 (2002-04-01), None
patent: WO 02/28829 (2002-04-01), None
patent: WO 02/30879 (2002-04-01), None
Kwon Ho Jeong, et al., Histone deacetylase inhibitor FK228 inhibits tumor Angiogenesis, Int'l J. of Cancer, vol. 97, No. 3, pp. 290-296 (Jan. 20, 2002).
Cancer Drug Design and Discovery Neidle, Stephen, ed. (Elsevier/Academic Press, 2008) pp. 427-431.
Gura, Science Nov. 7, 1997: vol. 278. No. 5340, pp. 1041-1042.
Roberts, Jr et al., JAMA 292(17): 2130-2140 (2004).
Kamb, Nature Reviews Drug Discovery 4, 161-165 (Feb. 2005).
Kola, Nature Reviews Drug Discovery 3, 711-715 (2004).
Leaf, Clifton, Health Administrator vol. XVIII, No. 1: 172-183, 2005.
“Expert Scientific Group on Phase One Clinical Trials Final Report” Nov. 30, 2006, pp. C1, C35-C38.
Andrews et al., 2000 “Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents,”Int. J. Parasitol., vol. 30, No. 6, pp. 761-768.
Barta et al., 2000, “Synthesis and activity of selective MMP inhibitors with an aryl backbone,”Bioorg. Med. Chem. Lett., vol. 10, No. 24, pp. 2815-2817.
Bernhard, D. et al., 1999, “Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts,”FASEB J., vol. 13, No. 14, pp. 1991-2001.
Bernstein et al., 2000, “Genomewide studies of histone deacetylase function in yeast,”Proc. Natl. Acad. Sci. USA, vol. 97, No. 25, pp. 13708-13713.
Brehm, A., et al., 1998, “Retinoblastoma protein recruits histone deacetylase to repress transcription,”Nature, 1998, vol. 391, pp. 597-601.
Chang et al., 2000, “Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation,”Nucleic Acids Res., vol. 28, No. 20, pp. 3918-3925.
Dangond et al., 1998, Differential Display Cloning of a Novel Human Histone Deacetylase (HDAC3) cDNA from PHA-Activated Immune Cells,Biochem. Biophys. Res. Commun., vol. 242, No. 3, pp. 648-652.
David, G., et al., 1998, “Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein,”Oncogene, vol. 16(19), pp. 2549-2556.
Davie, J.R., 1998, “Covalent modifications of histones: expression from chromatic templates,”Curr. Opin. Genet. Dev., vol. 8, pp. 173-178.
Desai, D., et al., 1999, “Chemopreventive efficacy of suberanilohydroxamic acid (SAHA), a cytodifferentiating agent, against tobacco-specific nitrosamine 4-(methylnitros-amino)-1-(3-pyridyI)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice,”Proceedings of the American Association for Cancer Research, Pevention/Basic Science and Clinical Studies 4, vol. 40, p. 362, Abstract No. 2396.
Desmarits, C., et al., 2001, Nickel-catalysed sequential amination of aryl- and heteroaryl di- and trichlorides,Tetrahedron, vol. 57, p. 7657-7664.
Emiliani, S., et al., 1998, “Characterization of a human RPD3 ortholog, HDAC3,”Proc. Natl. Acad. Sci. USA, vol. 95, p. 2795-2800.
Finnin et al., 1999, “Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors,”Nature, vol. 401, pp. 188-193.
Grozinger et al., 1999, “Three proteins define a class of human histone deacetylases related to yeast Hdalp,”Proc. Natl. Acad. Sci. USA, vol. 96, pp. 4868-4873.
Hartwig, J.F., et al., 1999, “Room-Temperature Palladium-Catalyzed Amination of Aryl Bromides and Chlorides and Extended Scope of Aromatic C-N Bond Formation with a Commercial Ligand,”J. Org. Chem., vol. 64, pp. 5575-5580.
Hoshikawa, Y., et al., 1994, “Trichostatin A Induces Morphological Changes and Gelsolin Expression by Inhibiting Histone Deacetylase in Human Carcinoma Cell Lines,”Exp. Cell. Res., vol. 214(1), pp. 189-197.
Hou et al., 2001, “Binding affinities for a series of selective inhibitors of gelatinase-A using molecular dynamics with a linear interaction energy approach,”J. Phys. Chem. B, vol. 105, No. 22, pp. 5304-5315.
Howe, L., et al., 1999, “Histone Acetyltransferase Complexes and Their Link to Transcription,”Crit. Rev. Eukaryot. Gene Expr., vol. 9(3-4), pp. 231-243.
Iavarone et al., 1999, “E2F and Histone Deacetylase Mediate Transforming Growth Factor β Repression ofcdc25Aduring Keratinocyte Cell Cycle Arrest,”Mol. Cell Biol., vol. 19, No. 1, pp. 916-922.
Jung, M., et al., 1999,Journal of Medicinal Chemistry(ACS, Washington, USA), vol. 42, No. 22, pp. 4669-4679.
Kao et al., 2000, “Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression,”Genes&Dev., vol. 14, p. 55-66.
Kijima et al., 1993, “Trapoxin, an Antitumor Cyclic Tetrapeptide, Is an Irreversible Inhibitor of Mammalian Histone Deacetylase*,”J. Biol. Chem., vol. 268, pp. 22429-22435.
Kim et al., 1999, “Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase,”Oncogene, vol. 18(15), pp. 2461-2470.
Kim, M.S., et al., 2001 “ Histone deacetylases induce angiogenesis by negative regulation of tumour suppressor genes,”Nature Medicine, vol. 7, No. 4, pp. 437-443.
Kimura et al., 1994, “Dual Modes of Action of Platelet-Derived Growth Factor and Its Inhibition by Trichostatin-A for DNA Synthesis in Primary Cultured Smooth Muscle Cells of Rat Aorta,”Biol. Pharm. Bull., vol. 17, No. 3, pp. 399-402.
Kitamura, K., et al., 2000, “Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinonic acid,”Br. J. Haematol., vol. 108(4), pp. 696-702.
Kouzarides, T., 1999, “Histone acetylases and deacetylases in cell proliferation,”Curr. Opin. Genet. Dev., vol. 9, No. 1, pp. 40-48.
Kuusisto et al., 2001, “Ubiquitin-Binding Protein p62 Expression is Induced during Apoptosis and Proteasomal Inhibition in Neuronal Cells,”Biochem. Biophys. Res. Commun., vol. 280, No. 1, pp. 223-228.
Kwon et al., 1998, “Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase,”Proc. Natl. Acad. Sci. USA, vol. 95, pp. 3356-3361.
Laherty, C.D., et al., 1997, “Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression,”Cell, vol. 89(3), pp. 349-356.
Lea and Tulsyan, 1995, &#
Dikovska Klara
Finn Paul W.
Gailite Vija
Kalvinsh Ivars
Lolya Daina
Leeser Erich A
Nixon & Vanderhye P.C.
Topotarget UK Limited
Wilson James O
LandOfFree
Carbamic acid compounds comprising a piperazine linkage as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbamic acid compounds comprising a piperazine linkage as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbamic acid compounds comprising a piperazine linkage as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2713252